The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Non-cancer-related deaths in patients with resectable locally advanced esophageal squamous cell carcinoma: A supplementary analysis of JCOG1109.
 
Hiroshi Imazeki
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yoshinori Ito
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Keisho Chin
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazuo Koyanagi
No Relationships to Disclose
 
Takashi Ogata
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Ono Pharmaceutical
 
Hiroki Hara
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Henlius (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeo Fujita
No Relationships to Disclose
 
Tetsuya Abe
No Relationships to Disclose
 
Fumitaka Endo
No Relationships to Disclose
 
Shigeru Tsunoda
Honoraria - Covidien/Medtronic; Ethicon/Johnson & Johnson; Kaken Pharmaceutical; Medicaroid; Olympus
 
Atsushi Takeno
No Relationships to Disclose
 
Yoshiaki Nagatani
Speakers' Bureau - Bristol-Meyers Squibb; Chugai Pharma; Daiichi-Sankyo; MSD; Ono Pharmaceutical
 
Hisayuki Matsushita
No Relationships to Disclose
 
Hiroshi Sato
No Relationships to Disclose
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical
 
Kota Kawabata
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Hiroya Takeuchi
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nihonkayaku; Novartis; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Sysmex; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tanabe Mitsubishi Pharmaceutical (Inst)